Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
What to look forward to in GaBI Journal, 2021, Issue 2 / Professor Philip D Walson, MD
Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers / Shalini Harikrishnan, BSc; Ka-Liong Tan, DPhil; Kar Ming Yee, BPharm; Alia Shagari Ahmad Shukri, MSc; N Ramana Reddy, MBBS; Chewy Wuei Leong, PhD
Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation / Kelly Canham, BSc Hons; Claire Newcomb, MSc
Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching / Mansour Somaily, MD; Hana Alahmari, MD; Wejdan Abbag; Shahenda Yousif, MD; Nawar Tayfour, MD; Nouf Almushayt; Saleh Alhusayni, MD; Saeed Almajadiah, MD
Variation in the prices of oncology medicines across Europe and the implications for the future / Brian Godman, BSc, PhD; Steven Simoens, MSc, PhD; Amanj Kurdi, BSc, PhD; Gisbert Selke; John Yfantopoulos; Andrew Hill, PhD, et al.
Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study / Pieter J Glerum, MSc; Mert Hayta, PharmD, MSc; David M Burger, PharmD, PhD; Cees Neef, PharmD, PhD; Marcel L Bouvy, PharmD, PhD; Marc Maliepaard, PhD
A critical review of substitution policy for biosimilars in Canada / Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes / Marta Zuccarelli, PharmD; Benjamin Micallef, PharmD; Mark Cilia, PharmD; Anthony Serracino-Inglott, PharmD; Professor John-Joseph Borg, PhD
An overview of the current status of follow-on biologicals in Iran / Farhang Rezaei, PharmD; Nassim Anjidani, PharmD
Microbiological, scientific and regulatory perspectives of hand sanitizers / Adjunct Associate Professor Sia Chong Hock, BSc Pharm, MSc; Tan Ying Ting, BSc Pharm (Hons); Associate Professor Chan Lai Wah, BSc Pharm (Hons)
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD
Use of biologicals in dermatology – following the agreed path or going off-piste? A brief report / Michael Wilcock, MPhil; Andrew Pothecary, MSc
Abstracted Scientific Content
Repurposing non-oncology drugs for cancer treatment / GaBI Journal Editor
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.